Toborinone | CAS#143343-83-3 | inhibitor

MedKoo Cat#: 584923 | Name: Toborinone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Toborinone is a phosphodiesterase III inhibitor.

Chemical Structure

Toborinone

CAS#143343-83-3

Theoretical Analysis

MedKoo Cat#: 584923

Name: Toborinone

CAS#: 143343-83-3

Chemical Formula: C21H24N2O5

Exact Mass: 384.1685

Molecular Weight: 384.43

Elemental Analysis: C, 65.61; H, 6.29; N, 7.29; O, 20.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Toborinone; OPC-18790; OPC18790; OPC 18790

IUPAC/Chemical Name

(+-)-6-(2-Hydroxy-3-(veratrylamino)propoxy)carbostyril

InChi Key

BYKYPZBCMBEEGU-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H24N2O5/c1-26-19-7-3-14(9-20(19)27-2)11-22-12-16(24)13-28-17-5-6-18-15(10-17)4-8-21(25)23-18/h3-10,16,22,24H,11-13H2,1-2H3,(H,23,25)

SMILES Code

O=C1NC2=C(C=C(OCC(O)CNCC3=CC=C(OC)C(OC)=C3)C=C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 384.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tammara B, Trang JM, Miyamoto G, Kitani M, Brisson J, Bramer SL. The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6. J Clin Pharmacol. 2002 May;42(5):492-500. PubMed PMID: 12017343. 2: Kageyama K, Mizobe T, Nozuchi S, Hiramatsu N, Nakajima Y, Aoki H. Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry. J Anesth. 2004;18(2):107-12. PubMed PMID: 15127258. 3: Sugiyama A, Satoh Y, Hashimoto K. Electropharmacologic effects of a new phosphodiesterase III inhibitor, toborinone (OPC-18790), assessed in an in vivo canine model. J Cardiovasc Pharmacol. 2001 Aug;38(2):268-77. PubMed PMID: 11483877. 4: Semeniuk LM, Belenkie I, Tyberg JV. Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure. Circulation. 1998 Jul 7;98(1):58-63. PubMed PMID: 9665061. 5: Tammara B, Trang JM, Kitani M, Miyamoto G, Bramer SL. The pharmacokinetics of toborinone in subjects with congestive heart failure and concomitant renal impairment and/or concomitant hepatic impairment. J Clin Pharmacol. 2002 Dec;42(12):1318-25. PubMed PMID: 12463726. 6: Ishikawa M, Koga K, Fujiki H, Mori T, Yabuuchi Y. Comparative study of toborinone (OPC-18790) and milrinone on energy metabolism in microembolized guinea pig hearts. Life Sci. 1997;61(23):2351-8. PubMed PMID: 9408058. 7: MacGowan GA. Clinical overview of the novel inotropic agent toborinone. Expert Opin Investig Drugs. 2000 May;9(5):1109-17. Review. PubMed PMID: 11060731. 8: Kocic I. Toborinone Otsuka Pharmaceutical Co Ltd. IDrugs. 1998 Sep;1(5):584-94. PubMed PMID: 18465598. 9: Kitani M, Miyamoto G, Nagasawa M, Yamada T, Matsubara J, Uchida M, Odomi M. Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. Drug Metab Dispos. 1997 Jun;25(6):663-74. PubMed PMID: 9193867. 10: Itoh S, Mori T, Fujiki H, Tominaga M. Effects of toborinone on myocardial oxygen consumption in pacing-induced heart failure dogs. Arzneimittelforschung. 1996 Dec;46(12):1105-9. PubMed PMID: 9006782. 11: Izumoto H, Fujiki H, Kawazoe K. Vascular relaxant effects of toborinone on the isolated canine internal mammary artery. Surg Today. 2001;31(10):885-90. PubMed PMID: 11759883. 12: Orito K, Takase H, Fujiki H, Mori T. Effects of toborinone (OPC-18790), a new positive inotropic agent, on action potential in guinea pig sinoatrial node: compared with milrinone and E-4031. Jpn J Pharmacol. 1996 Sep;72(1):79-82. PubMed PMID: 8902604. 13: Bito H, Kato N, Maruyama K, Kadotani H, Ogawa R. [Effects of toborinone on systemic circulation in patients under general anesthesia]. Masui. 1997 Jul;46(7):900-9. Japanese. PubMed PMID: 9251504. 14: Hirata T, Akamatsu T, Horinokuchi N, Uchida O, Kuro M. Study on the effectiveness of toborinone (OPC-18790) in the treatment of heart failure in patients following cardiac surgery. Arzneimittelforschung. 1999 Jun;49(6):499-503. PubMed PMID: 10417865. 15: Takase H, Orito K, Mori T, Fujiki H, Sekiguchi K, Tominaga M, Iijima T. Positive inotropic and chronotropic effects of toborinone and its electrophysiological properties in the isolated hearts of rabbits and guinea-pigs. Arzneimittelforschung. 1996 Jun;46(6):579-86. Erratum in: Arzneimittelforschung 1997 May;47(5):678. PubMed PMID: 8767347. 16: Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis. 1998 Nov-Dec;41(3):207-24. Review. PubMed PMID: 9872607. 17: Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002 Aug;4(4):515-29. PubMed PMID: 12167393. 18: Young JB. New therapeutic choices in the management of acute congestive heart failure. Rev Cardiovasc Med. 2001;2 Suppl 2:S19-24. Review. PubMed PMID: 12439358. 19: Feldman AM, Strobeck JE. Quinolinone derivatives in the management of congestive heart failure. Coron Artery Dis. 1994 Feb;5(2):107-11. Review. PubMed PMID: 8180742. 20: Yang T, Snyders DJ, Roden DM. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. J Pharmacol Exp Ther. 1997 Mar;280(3):1170-5. PubMed PMID: 9067300.